These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 27463974)

  • 61. Cerebrospinal fluid biomarkers in Parkinson disease.
    Parnetti L; Castrioto A; Chiasserini D; Persichetti E; Tambasco N; El-Agnaf O; Calabresi P
    Nat Rev Neurol; 2013 Mar; 9(3):131-40. PubMed ID: 23419373
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Tiny But Mighty: Promising Roles of MicroRNAs in the Diagnosis and Treatment of Parkinson's Disease.
    Wang Y; Yang Z; Le W
    Neurosci Bull; 2017 Oct; 33(5):543-551. PubMed ID: 28762215
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Buntanetap, a Novel Translational Inhibitor of Multiple Neurotoxic Proteins, Proves to Be Safe and Promising in Both Alzheimer's and Parkinson's Patients.
    Fang C; Hernandez P; Liow K; Damiano E; Zetterberg H; Blennow K; Feng D; Chen M; Maccecchini M
    J Prev Alzheimers Dis; 2023; 10(1):25-33. PubMed ID: 36641607
    [TBL] [Abstract][Full Text] [Related]  

  • 64. miRNAs as Circulating Biomarkers for Alzheimer's Disease and Parkinson's Disease.
    Mushtaq G; Greig NH; Anwar F; Zamzami MA; Choudhry H; Shaik MM; Tamargo IA; Kamal MA
    Med Chem; 2016; 12(3):217-25. PubMed ID: 26527155
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Essential Features and Use Cases of the Cerebrospinal Fluid Proteome Resource (CSF-PR).
    Guldbrandsen A; Farag YM; Lereim RR; Berven FS; Barsnes H
    Methods Mol Biol; 2019; 2044():377-391. PubMed ID: 31432427
    [TBL] [Abstract][Full Text] [Related]  

  • 66. CSF and blood biomarkers for Parkinson's disease.
    Parnetti L; Gaetani L; Eusebi P; Paciotti S; Hansson O; El-Agnaf O; Mollenhauer B; Blennow K; Calabresi P
    Lancet Neurol; 2019 Jun; 18(6):573-586. PubMed ID: 30981640
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Neural regeneration therapies for Alzheimer's and Parkinson's disease-related disorders.
    Reddy AP; Ravichandran J; Carkaci-Salli N
    Biochim Biophys Acta Mol Basis Dis; 2020 Apr; 1866(4):165506. PubMed ID: 31276770
    [TBL] [Abstract][Full Text] [Related]  

  • 68. What is the Clinical Significance of Cerebrospinal Fluid Biomarkers in Parkinson's disease? Is the Significance Diagnostic or Prognostic?
    Kim D; Paik JH; Shin DW; Kim HS; Park CS; Kang JH
    Exp Neurobiol; 2014 Dec; 23(4):352-64. PubMed ID: 25548535
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach.
    van Dijk KD; Teunissen CE; Drukarch B; Jimenez CR; Groenewegen HJ; Berendse HW; van de Berg WD
    Neurobiol Dis; 2010 Sep; 39(3):229-41. PubMed ID: 20451609
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Biomarkers in Randomized Clinical Trials: Magnetic Resonance Imaging.
    Whitwell JL
    Front Neurol Neurosci; 2016; 39():101-8. PubMed ID: 27463684
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Ceruloplasmin is increased in cerebrospinal fluid in Alzheimer's disease but not Parkinson's disease.
    Loeffler DA; DeMaggio AJ; Juneau PL; Brickman CM; Mashour GA; Finkelman JH; Pomara N; LeWitt PA
    Alzheimer Dis Assoc Disord; 1994; 8(3):190-7. PubMed ID: 7986488
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Rethinking on the concept of biomarkers in preclinical Alzheimer's disease.
    Berti V; Polito C; Lombardi G; Ferrari C; Sorbi S; Pupi A
    Neurol Sci; 2016 May; 37(5):663-72. PubMed ID: 26792010
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Normal cerebrospinal fluid glutathione concentrations in Parkinson's disease, Alzheimer's disease and multiple system atrophy.
    Konings CH; Kuiper MA; Teerlink T; Mulder C; Scheltens P; Wolters EC
    J Neurol Sci; 1999 Oct; 168(2):112-5. PubMed ID: 10526192
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Innovative Biomarkers for Alzheimer's Disease: Focus on the Hidden Disease Biomarkers.
    Ghidoni R; Squitti R; Siotto M; Benussi L
    J Alzheimers Dis; 2018; 62(4):1507-1518. PubMed ID: 29504534
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Reduced cerebrospinal fluid mitochondrial DNA is a biomarker for early-stage Parkinson's disease.
    Pyle A; Brennan R; Kurzawa-Akanbi M; Yarnall A; Thouin A; Mollenhauer B; Burn D; Chinnery PF; Hudson G
    Ann Neurol; 2015 Dec; 78(6):1000-4. PubMed ID: 26343811
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Neurotransmitter measures in the cerebrospinal fluid of patients with Alzheimer's disease: a review.
    Strac DS; Muck-Seler D; Pivac N
    Psychiatr Danub; 2015 Mar; 27(1):14-24. PubMed ID: 25751428
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Signatures of glial activity can be detected in the CSF proteome.
    Eninger T; Müller SA; Bacioglu M; Schweighauser M; Lambert M; Maia LF; Neher JJ; Hornfeck SM; Obermüller U; Kleinberger G; Haass C; Kahle PJ; Staufenbiel M; Ping L; Duong DM; Levey AI; Seyfried NT; Lichtenthaler SF; Jucker M; Kaeser SA
    Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2119804119. PubMed ID: 35666874
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Evaluation of Metabolic and Synaptic Dysfunction Hypotheses of Alzheimer's Disease (AD): A Meta-Analysis of CSF Markers.
    Manyevitch R; Protas M; Scarpiello S; Deliso M; Bass B; Nanajian A; Chang M; Thompson SM; Khoury N; Gonnella R; Trotz M; Moore DB; Harms E; Perry G; Clunes L; Ortiz A; Friedrich JO; Murray IVJ
    Curr Alzheimer Res; 2018; 15(2):164-181. PubMed ID: 28933272
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Unraveling Pathophysiological Mechanisms of Parkinson's Disease: Contribution of CSF Biomarkers.
    Farotti L; Paolini Paoletti F; Simoni S; Parnetti L
    Biomark Insights; 2020; 15():1177271920964077. PubMed ID: 33110345
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinson's disease: protocol for a systematic review and individual participant data meta-analysis.
    Eusebi P; Hansson O; Paciotti S; Orso M; Chiasserini D; Calabresi P; Blennow K; Parnetti L
    BMJ Open; 2017 Nov; 7(11):e018177. PubMed ID: 29170290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.